June 14, 2016

Poxel Makes Available to the Public Its 2015 Reference Document

LYON, France--(BUSINESS WIRE)-- Regulatory News:

POXEL SA (Paris:POXEL) (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative drugs to treat type 2 diabetes, informs its shareholders and the financial community that its 2015 Registration Document was made available to the public and registered with the AMF as of June 13, 2016 under the number R. 16-053.

The document is available on the AMF website (www.amf-france.org) and on the website of the company (www.poxel.com) in the Investors section.

About Imeglimin

Imeglimin is the first in a new chemical class of oral anti-diabetic agents, the Glimins. Imeglimin acts on three main target organs involved in glucose homeostasis: the liver, muscle, and the pancreas. Imeglimin's unique mechanism of action targets the mitochondrial bioenergetics. This distinct mode of action compared to existing treatments for type 2 diabetes makes Imeglimin a prime candidate in monotherapy and to complement other treatments such as metformin or sitagliptin.

About Poxel

Poxel uses its development expertise in metabolism to advance a pipeline of drug candidates focused on the treatment of type 2 diabetes. We have successfully completed our Phase 2 trials for our first-in-class lead product, Imeglimin, which targets mitochondrial dysfunction, in the U.S. and EU and have entered Phase 2b clinical development in Japanese patients. We are advancing our second program, PXL770, a direct AMPK activator, which is in Phase 1 development. We intend to generate further growth through strategic partnerships and pipeline development. (Euronext: POXEL, www.poxel.com)

View source version on businesswire.com:
http://www.businesswire.com/news/home/20160614006225/en/

Poxel SA
Jonae R. Barnes
Senior Vice President, Investor Relations and Public Relations
jonae.barnes@poxelpharma.com
+1 617 818 2985

or
Investor relations / Media - EU/US
MacDougall Biomedical Communications
Gretchen Schweitzer or Stephanie May
smay@macbiocom.com
+ 49 89 2424 3494 or + 49 175 571 1562
or
Investor relations / Media - France
NewCap
Florent Alba / Nicolas Merigeau
poxel@newcap.fr
+ 33 1 44 71 98 55

Source: POXEL